Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Jie SuSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.ORCID 0009-0006-6579-3904
Yue ZhaoSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.ORCID 0000-0002-6818-2352
Pierre ColemanSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.ORCID 0000-0001-9889-576X
Xiaoping YangKing's College London, Proteomics Facility, Centre of Excellence for Mass Spectrometry, The James Black Centre, 125 Coldharbour Lane, London SE5 9NU, UK.ORCID 0009-0004-3542-4038
Mark HoltSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, Randall Centre for Cell and Molecular Biophysics, New Hunt's House, London SE1 1UL, UK.ORCID 0000-0001-7775-8539
Janice RaabeInstitute of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.ORCID 0009-0005-7547-1514
Friederike CuelloInstitute of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.ORCID 0000-0003-1612-1715
Ajay ShahSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The James Black Centre, 125 Coldharbour Lane, London SE5 9NU, UK.ORCID 0000-0002-6547-0631
Michael J ShattockSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.ORCID 0000-0001-6242-7585
Min ZhangSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The James Black Centre, 125 Coldharbour Lane, London SE5 9NU, UK.ORCID 0000-0003-1657-1337
Joseph R BurgoyneSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, The British Heart Foundation Centre of Excellence, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.ORCID 0000-0001-7325-7382
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent condition associated with substantial morbidity and mortality, yet effective therapeutic options remain limited. As oxidation of Cys
Indexed as
Cyclic GMP-Dependent Protein Kinase Type ICysteineHeart FailureStroke VolumeAnimalsCoumarinsHumansCoumarinsCyclic GMP-Dependent Protein Kinase Type ICysteine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.